






Adalimumab Timeline



FWD = Final Written Decision

Technology: Adalimumab is a human monoclonal antibody that inhibits tumor necrosis factor alpha (TNFα). TNFα is a cytokine cell signaling protein that is involved in the inflammatory response that occurs in autoimmune diseases.

	<i>AbbVie v. Alvotech</i> 1:21-cv-02899 (N.D. Ill.) Settled (cont'd below)	<i>AbbVie v. Amgen</i> 1:16-cv-00666 (D. Del.) Settled	<i>AbbVie v. Boehringer Ingelheim</i> 1:17-cv-01065 (D. Del.) Settled	<i>AbbVie v. Alvotech</i> 1:21-cv-02258 (N.D. Ill.) Settled <i>Alvotech v. AbbVie</i> 1:21-cv-05645 (N.D. Ill.) Dismissed	<i>Amgen v. AbbVie</i> IPR2015-01514 Institution denied	<i>Amgen v. AbbVie</i> IPR2015-01517 Institution denied	<i>Coherus v. AbbVie</i> IPR2017-00822, IPR2017-00823 Institution denied	<i>Coherus v. AbbVie</i> IPR2017-00826 / IPR2017-01008 Institution denied	<i>Coherus v. AbbVie</i> IPR2017-00827 / IPR2017-01009 Institution denied
8,420,081				x					
8,663,945	x	x							
8,911,964	x	x							
8,916,157		x			x				
8,916,158					x	x			
8,926,975			x	x					
8,961,973		x		x					
8,986,693	x	x							
9,018,361			x						
9,090,867	x		x						
9,085,619				x			x	x	x
9,096,666	x	x	x						
9,220,781		x							
9,255,143			x						
9,266,949	x		x						
9,272,041		x	x						
9,359,434	x	x							
9,365,645		x							
9,546,212	x		x						

FWD = Final Written Decision

Spotlight On: Adalimumab

October 31, 2023

	<i>AbbVie v. Alvotect</i> 1:21-cv-02899 (N.D. Ill.) Settled (cont'd)	<i>Coherus v. AbbVie</i> IPR2016-00172 FWD: All claims unpatentable; Appeal No. 17-2304 Affirmed (U.S. as Intervenor, Coherus settled)	<i>Boehringer Ingelheim v. AbbVie</i> IPR2016-00408, IPR2016-00409 FWD: All claims unpatentable; Appeal Nos. 17-2362 and 17-2363 Affirmed (U.S. as Intervenor, Boehringer Ingelheim settled)	<i>Coherus v. AbbVie</i> IPR2016-00188 FWD: All claims unpatentable; Appeal No. 17-2305 Affirmed (U.S. as Intervenor, Coherus settled)	<i>Coherus v. AbbVie</i> IPR2016-00189 FWD: All claims unpatentable; Appeal No. 17-2306 Affirmed (U.S. as Intervenor, Coherus settled)	<i>Sandoz v. AbbVie</i> IPR2017-01824 Institution denied; Request for rehearing denied; Appeal No. 18-2142 settled	<i>Sandoz v. AbbVie</i> IPR2018-00002 Institution denied; Appeal No. 18-2143 settled
8,889,135		x	x				
9,017,680				x			
9,073,987					x		
9,512,216	x					x	x
		<i>Sandoz v. AbbVie</i> IPR2017-01823 Institution denied	<i>Sandoz v. AbbVie</i> IPR2017-01987 Institution denied; Settled during request for rehearing	<i>Sandoz v. AbbVie</i> IPR2017-01988 Institution denied; Settled during request for rehearing	<i>Sandoz v. AbbVie</i> IPR2017-02106 Settled after institution Coherus settled)	<i>Sandoz v. AbbVie</i> IPR2017-02105 Settled after institution	<i>Coherus v. AbbVie</i> IPR2016-01018 Institution denied
8,802,100		x					
8,911,737	x		x				
8,974,790	x			x			
9,067,992	x				x		
9,090,689	x					x	
9,114,166							x
		<i>Sandoz v. AbbVie</i> IPR2018-00156 Institution denied		<i>AbbVie v. Sandoz</i> 3:18-cv-12668 (D.N.J.) Settled		<i>Coherus v. Amgen</i> [Related to Amjevita™] 1:19-cv-00139 (D. Del.) Settled	
9,187,559	x	x		x			
9,750,808				x			
10,155,039						x	
10,159,732						x	
10,159,733						x	
10,207,000						x	

FWD = Final Written Decision

Spotlight On:
Adalimumab

October 31, 2023

	AbbVie v. Alvotech 1:21-cv-02899 (N.D. Ill.) Settled (cont'd)				
6,805,686	x	9,090,688	x	9,550,826	x
8,231,876	x	9,102,723	x	9,624,295	x
8,708,968	x	9,150,645	x	9,669,093	x
8,715,664	x	9,181,337	x	9,683,033	x
8,808,700	x	9,181,572	x	9,708,400	x
8,883,156	x	9,234,032	x	9,957,318	x
8,889,136	x	9,273,132	x		
8,895,009	x	9,284,370	x		
8,906,372	x	9,284,371	x		
8,906,373	x	9,290,568	x		
8,906,646	x	9,315,574	x		
8,916,153	x	9,328,165	x		
8,961,974	x	9,334,319	x		
8,992,926	x	9,339,610	x		
8,999,337	x	9,346,879	x		
9,061,005	x	9,499,614	x		
9,062,106	x	9,499,616	x		
9,085,618	x	9,505,834	x		
9,085,620	x	9,522,953	x		

FWD = Final Written Decision